ADORA2A and inflammatory bowel disease: PSB-15826 emerged as the most potent AR agonist (sub-μM EC50 on A2AR, in functional assays [179]) among a series of tested analogues (originally designed and developed within a research programme focusing on anti-inflammatory agents for inflammatory bowel disease[228]) in a study conducted by Fuentes et al. [179].